Skip to content

Jacqueline L von Salm

6 papers in the library · 8 citations · publishing 2024-2026

Papers

Sort Most recent Most cited

Synthesis and BiologicalEvaluation of 4‑Bromo-N,N-dimethyltryptamine(4-Br-DMT): A Synthetic BuildingBlock for Future Analog Development

Figshare June 23, 2026 Elena Bray, Grant C. Glatfelter, Alexander D. Maitland et al.

The ongoing psychedelic renaissance has prompted a renewed search for novel drugs based on modifying existing psychedelic motifs. In this study, a synthesis of 4-bromo-N,N-dimethyltryptamine (4-Br-DMT) was achieved and used as a late-stage intermediate for analog development. Specifically, we were able to synthesize and access novel molecules by forming carbon–carbon bonds at the C4 position...

Synthesis and Biological Evaluation of 4-Bromo- N,N- dimethyltryptamine (4-Br-DMT): A Synthetic Building Block for Future Analog Development

ACS Omega June 23, 2026 Elena Bray, Grant C. Glatfelter, Alexander D. Maitland et al.

-dimethyltryptamine (DMT). Overall, the data indicate that 4-Br-DMT has a serotonergic profile without psychedelic-like effects in mice but has a reduced safety profile compared to psilocin and DMT.

Serotonergic Polypharmacology of 2-Halogenated Tryptamines.

bioRxiv : the preprint server for biology April 21, 2026 Jeanine Yacoub, Elena Bray, Jude Bayyat et al.

Serotonergic psychedelics such as N,N-dimethyltryptamine (DMT) and 4-phosphoryloxy-N,N-dimethyltryptamine (psilocybin) show therapeutic promise for psychiatric and neurodegenerative disorders but may be limited by liabilities from serotonin (5-HT)-2A mediated psychoactive effects and potential cardiotoxicity via 5-HT2B activation. To address these limitations, we designed and synthesized...

Pharmacodynamic effects and plasma pharmacokinetics of N, N-dimethyltryptamine after intranasal versus subcutaneous administration in male rats.

Psychopharmacology November 15, 2025 Michael H. Baumann, Grant C. Glatfelter, Sara E Walton et al. 1 citation

There is growing interest in the therapeutic utility of psychedelic compounds that act as serotonin-2 A receptor (5-HT2A) agonists. N,N-dimethyltryptamine (DMT) is a 5-HT2A agonist that produces intense and short-lived psychedelic subjective effects, but the compound requires non-oral routes of administration that bypass gastrointestinal metabolism. Intranasal (IN) delivery of DMT represents...

Editorial: Beyond psilocybin: exploring the clinical potential of alternative and novel psychedelics.

Front Psychiatry April 23, 2025 Martin L Williams, Deborah Rudin, Yasmin Schmid et al.

However, psilocybin is but one of scores of compounds belonging to two main chemical classesphenethylamines and tryptamines -along with ergolines and an expanding array of other (mostly heterocyclic) alkaloids -that act as agonists of the serotonin 5-HT2A, 5-HT2C and 5-HT1A receptors responsible for the various phenomenological and putative therapeutic effects of classic psychedelics (8). In...

Novel extended-release transdermal formulations of the psychedelic N,N-dimethyltryptamine (DMT).

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences August 1, 2024 Christopher G Witowski, Mika R Hess, Nate T Jones et al. 7 citations

There is considerable evidence from the literature that psychedelics, such as N,N-dimethyltryptamine (DMT), are safe and effective treatments for depression. However, clinical administration to induce psychedelic effects and expensive psychotherapy-assisted treatments likely limit accessibility to the average patient. There is emerging evidence that DMT promotes positive behavioral changes in...